While GLP-1 and GLP-1/GIP medications are generally considered cost-effective for treating obesity in targeted populations [65,66,67], alternative strategiessuch as expanding bariatric surgery access, enhancing lifestyle intervention programmes, pharmaceutical management of cardiometabolic comorbidities, or population-level policiesshould also be considered
These are GLP-1, GIP, and glucagon pathways
CJC-1295 is a synthetic analogue of growth hormone releasing hormone, or GHRH
The 25% Boost A major study found that NAD+ supplementation increased insulin sensitivity in skeletal muscle by 25% in prediabetic women
Patients experiencing mood changes whilst taking Ozempic should discuss these with their GP for comprehensive assessment
For further reading, take a look at this useful article from Womens Health, which explores the wider conversation around natural GLP-1 supplements